Overview

Moxonidine Effects on Neuropeptide Y

Status:
Completed
Trial end date:
2014-06-30
Target enrollment:
Participant gender:
Summary
Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension
Phase:
Phase 4
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Treatments:
Moxonidine